NOVAVAX INC Contract with Customer, Liability, Noncurrent
NOVAVAX INC (NVAX) had Contract with Customer, Liability, Noncurrent of $356.75 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:ContractWithCustomerLiabilityNoncurrent · last filed 2026-08-06
- 2026-06-30: Contract with Customer, Liability, Noncurrent $356.75M.
- 2026-03-31: Contract with Customer, Liability, Noncurrent $359.27M.
- 2025-12-31: Contract with Customer, Liability, Noncurrent $358.94M.
- 2025-09-30: Contract with Customer, Liability, Noncurrent $397.11M.
| Period end | Contract with Customer, Liability, Noncurrent | Contract with Customer, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $356.75M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $359.27M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $358.94M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $397.11M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $399.26M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $409.56M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $446.82M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $515.37M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $533.43M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $841.47M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $622.21M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $608.84M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $606.94M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $274.06M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $179.41M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $1.04B 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $814.63M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $441.75M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $172.50M 10-K · filed 2024-02-28 | $172.53M 10-K · filed 2022-03-01 |
| 2020-12-31 | $0.00 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |